Answers are grounded in this paper and cite their sources.
Preeclampsia remains a formidable and heterogenous multisystemic obstetric syndrome, accounting for a substantial proportion of severe maternal morbidity and iatrogenic preterm birth worldwide. Despite decades of intense investigation, the clinical translation of predictive tools into effective preventive strategies continues to be hampered by the intricate pathophysiological heterogeneity of the disorder and the modest performance of traditional clinical risk factor-based screening. The advent of high-throughput omics technologies and a more granular understanding of the angiogenic-antiangiogenic imbalance, placental senescence, and syncytiotrophoblast-derived extracellular vesicle signaling have catalyzed the identification of an expanding array of candidate biomarkers, particularly those detectable within the first trimester maternal circulation. These putative indices, ranging from the well-established placental growth factor and pregnancy-associated plasma protein-A to novel candidates such as cell-free mitochondrial DNA, circulating non-coding RNAs, and specific inflammatory interleukins, offer a nuanced window into the subclinical placental dysfunction that precedes the clinical manifestation of hypertension and proteinuria by several weeks or even months.
No takes yet. Share an insight, caveat, or question.
Padilla* et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: